
TZ-2 (Tirz)
R895 – R2 282
Independently lab-tested by Janoshik
≥99% purity, verified by Janoshik Analytical (Czech Republic) — the industry-standard third-party HPLC lab. A Certificate of Analysis accompanies every batch.
- LOT
- PSA-TZ2-2026
- PURITY
- ≥99%
- COA
- JANOSHIK ✓
- BATCH
- 2026-07-06
Purity: ≥99%
Storage: Refrigerate after reconstitution.
TZ-2 is a dual GIP and GLP-1 receptor agonist representing the next generation of metabolic peptide research. Studied extensively for its role in glucose homeostasis, appetite regulation, and significant body weight reduction in preclinical models.
- Dual GIP/GLP-1 agonism
- Glucose homeostasis research
- Appetite regulation studies
- Body weight reduction research
Frequently bought together
Complete your protocol
R4 425,00


What's Included
- 1x Research vial
- Certificate of Analysis
- Batch certification
- Storage instructions
Who It's For
- Metabolic researchers
- Diabetes research labs
- Weight management studies
How It Works
- 1Select MG variant
- 2Store per guidelines
- 3Implement research protocol
- 4Track metabolic markers
For research purposes only. Not for human use or consumption.
Clinical-grade compounding, not grey-market vials.
Scientific Oversight
HPCSA-registered GP review on file
Independent Lab Testing
99.0%+ purity threshold · COA per lot
Documented SOPs
ISO-style procedure control
Cold-Chain Integrity
2–8 °C controlled handoff
Medical Pathway
GP → script → SAHPRA-compliant pharmacy
Operational Legitimacy
POPIA · PCI-DSS · CIPC registered
3 Reviews
5.0
Based on 3 reviews
Mark D.
VerifiedMarch 19, 2026
Pre-ordered and received notification promptly when batch was ready. Quality is outstanding.
Dr. Williams
VerifiedMarch 15, 2026
Dual agonist research has been promising. Product purity is exactly as stated on the COA.
Anja R., Centurion
VerifiedMarch 11, 2026
Ordering was simple — no customs, fast delivery via local courier.
Delivery & Returns
Frequently Asked Questions
You Might Also Like
Best SellerIn StockGLP
RTT-RT3-10
RT3 (Reta)
CAS 2381089-83-2
Triple agonist targeting GLP-1, GIP, and glucagon receptors for metabolic research.
